KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Common Equity (2016 - 2026)

Idexx Laboratories has reported Common Equity over the past 17 years, most recently at $1.6 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 0.63% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 0.63%, while the annual FY2025 figure was $1.6 billion, 0.63% up from the prior year.
  • Common Equity for Q4 2025 was $1.6 billion at Idexx Laboratories, up from $1.6 billion in the prior quarter.
  • Over five years, Common Equity peaked at $1.6 billion in Q3 2024 and troughed at $457.0 million in Q2 2022.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 551.0% in 2021 and later crashed 38.92% in 2022.
  • Year by year, Common Equity stood at $690.0 million in 2021, then decreased by 11.78% to $608.7 million in 2022, then skyrocketed by 143.87% to $1.5 billion in 2023, then increased by 7.46% to $1.6 billion in 2024, then increased by 0.63% to $1.6 billion in 2025.
  • Business Quant data shows Common Equity for IDXX at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.